The odds ratio (OR) suggests that the risk of breast cancer is 6.5724 times higher in patients with INO80 deletion in the TNBC cluster than in those with other mutations, which is statistically significant [CI (4.55–9.49) and p < 0.0001]. Here, INO80 is linked to breast carcinoma.